Progenics Pharmaceuticals, Inc. is now a
subsidiary of Lantheus Holdings, Inc.
Investors Investors

Press Releases

Press Releases

All Releases
Jun 22, 2020
NORTH BILLERICA, Mass. & NEW YORK --(BUSINESS WIRE)--Jun. 22, 2020-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents
Jun 16, 2020
NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, announced that at a special meeting of its stockholders held earlier today,
May 18, 2020
- Met Primary Endpoint with a Correct Localization Rate of 84.8–87.0% - - 63.9% Change in Disease Management Plan Based on PyL Imaging Results - - Planned NDA Submission On Track for Early Third Quarter 2020 - NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc.
May 07, 2020
Pending Merger with Lantheus Holdings, Inc. for Combination of an Innovative Commercial Life Sciences Company with a Diversified Precision Diagnostics and Radiopharmaceutical Therapeutics Portfolio Planned NDA Submission for PyL TM On Track for Early Third Quarter 2020 First Quarter Sales of AZEDRA
Apr 23, 2020
NEW YORK, April 23, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call and webcast to review first quarter
Apr 14, 2020
NORTH BILLERICA, Mass. and New York, NY –  April 14, 2020 – Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and
Apr 02, 2020
NORTH BILLERICA, MA – April 2, 2020 – Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals,
Mar 13, 2020
NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the fourth quarter and full-year 2019. “The recent positive top line results from the Phase 3 CONDOR trial of PyL™ highlights the potential of our radiopharmaceutical
Feb 20, 2020
Combination to Create Robust Portfolio and Pipeline of Precision Diagnostic and Therapeutic Products Progenics Shareholders Will Receive 0.31 Shares of Lantheus Common Stock for Each Share of Progenics Stock in All-Stock Transaction, Represents Approximately 40% Ownership Stake in Combined Company
Feb 06, 2020
NEW YORK, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that three abstracts highlighting PyL TM ( 18 F-DCFPyL), I-131 1095,
Jan 21, 2020
NEW YORK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, issued the following letter to shareholders: January 21,
Jan 16, 2020
NEW YORK, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that an abstract highlighting data from its PSMA AI program has been
Dec 23, 2019
- Met Primary Endpoint With a Correct Localization Rate of 84.8–87.0%, Highlighting Strong Diagnostic Performance - Company Expects to Submit an NDA to the FDA in the Second Half of 2020 - Conference Call at 8:00 AM Eastern Time NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,
Dec 22, 2019
NEW YORK, Dec. 22, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call to review the top line results
Nov 25, 2019
NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that four abstracts highlighting PyL (¹⁸F-DCFPyL) have been selected
Nov 21, 2019
NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced its Board of Directors has appointed David W.
Nov 08, 2019
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it has delivered all consents and
Nov 07, 2019
Lantheus Holdings, Inc. to Acquire Progenics to Form an Innovative Commercial Life Sciences Company with a Diversified Portfolio of Precision Diagnostics and Radiopharmaceutical Therapeutics AZEDRA Commercial Dosing Progresses in U.S. as New Technology Add-On Payment Became Effective October 1st;
Nov 06, 2019
Warns Shareholders to Ignore Earlier and Illusory Consent Cutoff Set by Velan Urges Shareholders to Review the S-4 Filing that Will be Made the Week of November 11 about the Value Maximizing Lantheus Transaction in Order to Make a Fully Informed Final Decision about the Consent Solicitation and
Nov 04, 2019
November 17 is the Only Deadline for Velan’s Consent Solicitation Reminds Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17 NEW YORK, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc.